secwatch.observer — SEC 8-K summary
======================================

Issuer:     STAAR SURGICAL CO (STAA)
CIK:        0000718937
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0000718937-26-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STAAR Surgical appoints interim co-CEOs; reports China stabilization, EVO+ launch, cost cuts
--------------------------------------------------------------------------------

- Warren Foust and Deborah Andrews named Interim Co-CEOs after Alcon merger rejected by shareholders in Jan 2026.
- Cost reductions beat $225M second-half 2025 run rate target; operating expenses lowered significantly.
- China EVO ICL demand recovered at mid-single-digit rate in 2025; distributor inventories normalized.
- EVO+ received China regulatory approval mid-2025; early demand exceeds expectations; shipments began Nov 2025.
- FDA expanded EVO ICL age range to 21-60 in US, adding ~8M potential patients; new SVP hires in supply chain and APAC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/718937/000071893726000005/0000718937-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/718937/000071893726000005/staa-20260303.htm
  HTML page:      https://secwatch.observer/filing/0000718937-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer